195
Omalizumab: anti‐IgE monoclonal
antibody
•
IgG
1
kappa human framework
containing 5% murine antibody
complementarity‐determining
regions (MW ~150kD)
•
Binds circulating free IgE
•
Prevents IgE binding to high‐
and low‐affinity receptors
•
Minimal risk of anaphylaxis
•
Forms small, biologically inert
omalizumab:IgE complexes
•
Non‐complement fixing antibody
The inflammatory cascade in asthma – role
of IgE
Simposium
